CAR

Myeloid Therapeutics Presents Multiple Posters at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Retrieved on: 
화요일, 5월 7, 2024
CRISPR, Safety, CREATE, Gene editing, Vivo, MD, RNA, Canadian Aviation Regulations, Cell, Trial of the century, Primate, DNA, Patient, Gene, Society, Antigen, Messenger, Drug development, Annual general meeting, Therapy, Vaccine

CAMBRIDGE, Mass., May 7, 2024 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage immunology company, today announced multiple poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually. 

Key Points: 
  • "The data presented at ASGCT showcase that Myeloid continues to lead the field of in vivo immune cell engineering and RNA-enabled gene editing and delivery.
  • The data presented today underlies our in vivo mRNA CAR, MT-302, that continues to progress well in the ongoing clinical study.
  • We are expanding plans for MT-302's clinical use, given several inherent product advantages for patients," said Daniel Getts, Ph.D., Chief Executive Officer of Myeloid.
  • Poster presentation details and abstract highlights include:
    Myeloid has designed novel CARs that achieve expression and function in targeted immune cell populations.

Deerfield Management and Deerfield Foundation Announce Second Annual AML Summit and Recipients of American Society of Hematology (ASH) Peter Steelman Scholar Award

Retrieved on: 
월요일, 5월 6, 2024
University, Bone marrow, Summit, Cancer, Hospital, Blood, Oncology, Partnership, Research, AML, MSKCC, Senior, ASH, Patient, Society, Harvard Medical School, Boston Children's Hospital, Division, Dana–Farber Cancer Institute

NEW YORK, May 6, 2024 /PRNewswire/ -- Deerfield Management and the Deerfield Foundation announced today they will honor the 2023-2024 recipients of the American Society of Hematology (ASH) Peter Steelman Scholar Award at the second annual Acute Myeloid Leukemia (AML) Summit. The AML Summit convenes industry experts, leaders, and partners across healthcare to further advance research on this cancer of the bone marrow and blood.

Key Points: 
  • NEW YORK, May 6, 2024 /PRNewswire/ -- Deerfield Management and the Deerfield Foundation announced today they will honor the 2023-2024 recipients of the American Society of Hematology (ASH) Peter Steelman Scholar Award at the second annual Acute Myeloid Leukemia (AML) Summit.
  • The AML Summit convenes industry experts, leaders, and partners across healthcare to further advance research on this cancer of the bone marrow and blood.
  • Her research has identified novel molecular dependencies in this AML subtype, contributing to the development of targeted epigenetic drugs that are in early-phase clinical trials.
  • Dr. Haubner is a physician-scientist specializing in chimeric antigen receptor (CAR) therapies for safe and efficient targeting of AML.

Ginkgo Bioworks Announces Presentations at the Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Retrieved on: 
월요일, 5월 6, 2024
Gene therapy, Abstract, UTR, Machine learning, RNA therapeutics, RNA, Cell, Ginkgo, B cell, Automation, DNA, Therapy, Gene, Society, Acquisition, Messenger, Annual general meeting, NK, Vaccine

Ginkgo will present three posters in cell therapy and give one oral presentation in mRNA therapeutics.

Key Points: 
  • Ginkgo will present three posters in cell therapy and give one oral presentation in mRNA therapeutics.
  • These presentations demonstrate the power of Ginkgo's platform to drive innovation in the discovery and development of genetic medicines.
  • The addition of Patch Bio's assets opens up additional commercial opportunities in gene therapy, cell therapy, and RNA therapeutics and has the potential to accelerate progress on current programs.
  • Information on the poster presentations and oral presentation are listed below, and the full abstracts are available on the ASGCT meeting website .

Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting

Retrieved on: 
금요일, 5월 3, 2024
Cancer, Abstract, Cell, ADR, Patient, Gene, Society, IPSC, SLE, Therapy, SAN

SAN DIEGO, May 03, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that a late-breaking abstract featuring preclinical data from its FT522 program for autoimmune diseases will be featured at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, being held in Baltimore, Maryland on May 7-11, 2024.

Key Points: 
  • SAN DIEGO, May 03, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that a late-breaking abstract featuring preclinical data from its FT522 program for autoimmune diseases will be featured at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, being held in Baltimore, Maryland on May 7-11, 2024.
  • At the ASGCT conference, the Company will present multiple preclinical studies displaying the function of FT522 using peripheral blood mononuclear cells (PBMCs) sourced from unmatched donors with systemic lupus erythematosus (SLE).
  • These preclinical data demonstrate rapid and deep B-cell depletion, enhanced functional persistence, and elimination of alloreactive host immune cells, indicating that FT522 may deliver therapeutic benefit to patients with autoimmune diseases without requiring administration of conditioning chemotherapy.
  • Late-breaking abstracts are available on the ASGCT Annual Meeting website .

Valley Children's Receives Historic $15 Million Gift to Create Advanced Cell Therapy Program for Pediatric Cancer

Retrieved on: 
금요일, 5월 3, 2024
Cancer, Bone marrow, Protein, Haematopoietic system, Hospital, Travel, Health care, Research, History, Weapon, Acute lymphoblastic leukemia, Accreditation, Transplant, Patient, Nursing, Infection, COG, San Francisco Bay Area, Vaccine

MADERA, Calif., May 3, 2024 /PRNewswire/ -- Valley Children's Healthcare this week announced a historic donation of $15 million that will significantly enhance the hospital's ability to provide the most advanced bone marrow transplant and chimeric antigen receptor (CAR) T-cell therapy treatments to kids with cancer in the Central Valley.

Key Points: 
  • CAR T-cell therapy is an advanced genetically engineered therapy that uses the body's natural immune system to fight cancer and infections.
  • In a key CAR T-cell study in 2021, approximately 60% of children who underwent CAR T-cell therapy were cancer-free after five years.
  • The gift will support not only the establishment and accreditation of the program but also operational funding for its first 10 years.
  • "Because of this important donation, we will be able to establish a life-saving cellular and gene therapy program at Valley Children's.

Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer

Retrieved on: 
목요일, 5월 2, 2024
University, Cancer, Johns Hopkins Hospital, IND, Genetics, Johns Hopkins, Pancreas, Thomas Jefferson University, Patient, Macrophage, CARM, Louisiana State University, Associate, Therapy, Lumos, Medical college

PHILADELPHIA, May 2, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Eugene P. Kennedy, M.D., F.A.C.S. as the Company's Chief Medical Officer. Dr. Kennedy brings over 15 years of clinical and industry experience, including cross-functional leadership driving clinical development and regulatory strategies for oncology and immuno-oncology focused organizations. In the role of Chief Medical Officer, Dr. Kennedy will be responsible for overseeing Carisma's clinical development, regulatory and medical affairs functions.

Key Points: 
  • In the role of Chief Medical Officer, Dr. Kennedy will be responsible for overseeing Carisma's clinical development, regulatory and medical affairs functions.
  • "On behalf of Carisma, I am delighted to welcome Gene to our team," said Steven Kelly, President and Chief Executive Officer of Carisma.
  • Before joining Carisma, Dr. Kennedy served as Chief Medical Officer at Galera Therapeutics, where he oversaw the development of the company's radiotherapy in cancer.
  • Before Lumos, Dr. Kennedy held the role of Chief Medical Officer at NewLink Genetics, overseeing clinical trials across multiple product candidates and indications.

Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology

Retrieved on: 
목요일, 5월 2, 2024
Cancer, Area, Research, Patient, Synthetic biology, Therapy, Interest, SAN

TOKYO and SAN DIEGO, May 1, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Poseida Therapeutics, Inc. (NASDAQ: PSTX, President and CEO: Kristin Yarema, "Poseida") today announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas, "Xyphos") and Poseida have entered into a research collaboration and license agreement to develop novel convertibleCAR® programs by combining the innovative cell therapy platforms from each of the companies.

Key Points: 
  • Poseida is advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases.
  • In oncology, its pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors that address patient populations with high unmet medical need.
  • Xyphos will reimburse Poseida for costs incurred as part of the research agreement and will be responsible for the development and future commercialization of products generated from the collaboration.
  • In August 2023, Astellas and Poseida announced a strategic investment by Astellas to support Poseida's commitment to redefining cancer cell therapy.

BioWorld by Clarivate Explores the Future of CAR T Therapy in Mainland China in Special Report

Retrieved on: 
화요일, 4월 30, 2024
Cancer, CLVT, Traction, Intelligence, Environment, Therapy, Patent, CD19, Patient, Immune system, Growth, Pharmaceutical industry

LONDON, April 30, 2024 /PRNewswire/ -- BioWorld™ published by  Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, explores the growing investment in CAR T therapy development in mainland China in a new series titled "China's CAR T market comes of age." The report examines the dynamic realm of CAR T-cell therapies in China, including the rapid pipeline growth, deals, clinical trials and challenging issues surrounding patient access to very expensive and effective cancer therapeutics.

Key Points: 
  • CAR T (Chimeric Antigen Receptor T-cell) therapy represents a revolutionary approach to cancer treatment, harnessing the power of the body's immune system to target and destroy cancer cells.
  • As this groundbreaking treatment gains traction in the pharmaceutical sphere, the BioWorld special report provides valuable insights into its present state and future potential.
  • As of Jan. 31, 2024, there were more than 300 CAR T trials registered in China, surpassing the U.S. and becoming the country with the most CAR T therapy clinical trials.
  • The BioWorld special report investigates how CAR T development is coming of age in a country with the world's second-largest population."

BioWorld by Clarivate Explores the Future of CAR T Therapy in Mainland China in Special Report

Retrieved on: 
화요일, 4월 30, 2024
Cancer, CLVT, Traction, Intelligence, Environment, Therapy, Patent, CD19, Patient, Immune system, Growth, Pharmaceutical industry

LONDON, April 30, 2024 /PRNewswire/ -- BioWorld™ published by  Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, explores the growing investment in CAR T therapy development in mainland China in a new series titled "China's CAR T market comes of age." The report examines the dynamic realm of CAR T-cell therapies in China, including the rapid pipeline growth, deals, clinical trials and challenging issues surrounding patient access to very expensive and effective cancer therapeutics.

Key Points: 
  • CAR T (Chimeric Antigen Receptor T-cell) therapy represents a revolutionary approach to cancer treatment, harnessing the power of the body's immune system to target and destroy cancer cells.
  • As this groundbreaking treatment gains traction in the pharmaceutical sphere, the BioWorld special report provides valuable insights into its present state and future potential.
  • As of Jan. 31, 2024, there were more than 300 CAR T trials registered in China, surpassing the U.S. and becoming the country with the most CAR T therapy clinical trials.
  • The BioWorld special report investigates how CAR T development is coming of age in a country with the world's second-largest population."

CHOP Study Finds Healthcare Providers Play Crucial Role in Guiding Autistic Adolescents and Their Families into Adulthood

Retrieved on: 
월요일, 4월 29, 2024
Online, Bangladesh Technical Education Board, Spectrum, Learning, Hospital, CHOP, Research, DSM-IV codes, Health care, Doctor of Philosophy, Transport, CIRP, Licensure, Child, Caregiver, Children's Hospital of Philadelphia, Quality of life, Journal, Nursing

The study also highlighted the crucial role of healthcare providers in fostering collaborative decision-making around key milestones for adulthood, along with support strategies to help families assess driving readiness.

Key Points: 
  • The study also highlighted the crucial role of healthcare providers in fostering collaborative decision-making around key milestones for adulthood, along with support strategies to help families assess driving readiness.
  • Healthcare providers are eager to improve quality of life for autistic adolescents by acting as facilitators during this transitional time.
  • Providers recognized that working towards independence can offer significant benefits for autistic youths and their families.
  • Preparing to "Live a Life of Possibilities": Experiences of Healthcare Providers Readying Autistic Adolescents and Their Families for Independent Driving.